Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Eternivax Biomedical Inc. is handling 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, ALAM, DANYAL HASSAN, who is the busiest examiner with 1 pending action. The matter is being prosecuted in 1 distinct art unit, indicating a focused effort.
The company's current patent activity involves 1 pending office action, which is reviewed by 1 distinct examiner. This indicates a highly focused prosecution effort with a single individual and a single administrative unit involved in the pending matter. ALAM, DANYAL HASSAN is the sole point of contact, meaning his specific examination preferences will determine the outcome of the filing.
Managing 1 pending office action in 1 distinct art unit simplifies the administrative tracking of the portfolio. However, the lack of multiple matters means there is no diversification of risk across different examiners or units. The strategy for this 1 pending office action must be entirely tailored to the feedback provided by ALAM, DANYAL HASSAN to ensure a successful prosecution in the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18697448 | RECOMBINANT FUSION PROTEIN DERIVED FROM HR REGION OF S2 PROTEIN OF SARS-COV-2 AND APPLICATION OF RECOMBINANT FUSION PROTEIN | ALAM, DANYAL HASSAN | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18697448 | RECOMBINANT FUSION PROTEIN DERIVED FROM HR REGION OF S2 PROTEIN OF SARS-COV-2 AND APPLICATION OF RECOMBINANT FUSION PROTEIN | ALAM, DANYAL HASSAN | 1672 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEternivax Biomedical Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Danyal Hassan Alam has the most, with 1 of Eternivax Biomedical Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
